Wolfram Brugger

15.5k total citations · 3 hit papers
191 papers, 10.6k citations indexed

About

Wolfram Brugger is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Wolfram Brugger has authored 191 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 62 papers in Hematology and 56 papers in Immunology. Recurrent topics in Wolfram Brugger's work include Lymphoma Diagnosis and Treatment (37 papers), Immunotherapy and Immune Responses (37 papers) and Hematopoietic Stem Cell Transplantation (37 papers). Wolfram Brugger is often cited by papers focused on Lymphoma Diagnosis and Treatment (37 papers), Immunotherapy and Immune Responses (37 papers) and Hematopoietic Stem Cell Transplantation (37 papers). Wolfram Brugger collaborates with scholars based in Germany, United States and United Kingdom. Wolfram Brugger's co-authors include Lothar Kanz, Peter Brossart, Robert Möhle, Volker L. Reichardt, Frank Grünebach, Gernot Stuhler, Hans‐Jörg Bühring, Frank Bautz, Stefan Wirths and Malcolm A.S. Moore and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Wolfram Brugger

185 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 962 citations Mathias Rummel, N. Niederle et al. The Lancet profile →
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

2010 917 citations Federico Cappuzzo, Tudor–Eliade Ciuleanu et al. profile →
The Chemokine Receptor CXCR-4 Is Expressed on CD34+Hematopoietic Progenitors and Leukemic Cells and Mediates Transendothelial Migration Induced by Stromal Cell-Derived Factor-1

1998 536 citations Robert Möhle, Frank Bautz et al. Blood profile →

Peers

Countries citing papers authored by Wolfram Brugger

Since Specialization

Citations

This map shows the geographic impact of Wolfram Brugger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfram Brugger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfram Brugger more than expected).

Fields of papers citing papers by Wolfram Brugger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfram Brugger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfram Brugger. The network helps show where Wolfram Brugger may publish in the future.

Co-authorship network of co-authors of Wolfram Brugger

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfram Brugger. A scholar is included among the top collaborators of Wolfram Brugger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfram Brugger. Wolfram Brugger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process 2022 ·Transplantation and Cellular Therapy ·(unknown), Frederick Arce Vargas, (unknown), Claire Roddie, Paul Shaughnessy, Kevin J. Duffy, Wolfram Brugger, Michael Merges, Martin Pulé	1
2	Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma 2021 ·European Journal Of Haematology ·Christian Straka, Hans Salwender, Stefan Knop, Martin Vogel, (unknown), Bernd Metzner, Christian Langer, Herbert G. Sayer, Wolfram Jung, Heinz Dürk, Florian Bassermann, Martin Gramatzki, Wolf Rösler, Hans‐Heinrich Wolf, Wolfram Brugger, Monika Engelhardt, Thomas Fischer, Peter Liebisch, Hermann Einsele	4
3	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations 2016 ·Journal of Thoracic Oncology ·Barbara Klughammer, Wolfram Brugger, Federico Cappuzzo, Tudor–Eliade Ciuleanu, Tony Mok, Martin Reck, Eng Huat Tan, Paul Delmar, Gaëlle Klingelschmitt, (unknown), Olivia Spleiss, Lin Wu, David S. Shames	78
4	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update 2015 ·Leukemia & lymphoma ·Bruce D. Cheson, Wolfram Brugger, Gandhi Damaj, Martin Dreyling, Brad S. Kahl, Eva Kimby, Michinori Ogura, Eckhart Weidmann, Clemens‐Martin Wendtner, Pier Luigi Zinzani	64
5	Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial breakdown → 2013 ·The Lancet ·Mathias Rummel, N. Niederle, Georg Maschmeyer, Gamal-Andre Banat, Ulrich von Grünhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Dürk, Harald Balló, Martina Stauch, Fritz Roller, Juergen Barth, Dieter Hoelzer, Axel Hinke, Wolfram Brugger	962
6	Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors 2010 ·Journal of Cancer Research and Clinical Oncology ·Hans‐Georg Kopp, Stefan Wirths, Christoph Faul, Wolfgang Bethge, Stefan Scheding, Wolfram Brugger, Lothar Kanz, Wichard Vogel	2
7	Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients 2010 ·Molecular Therapy ·Susanne M. Rittig, Maik Haentschel, (unknown), Annkristin Heine, Martin Müller, Wolfram Brugger, Marius Horger, Olga Maksimovic, Arnulf Stenzl, Ingmar Hoerr, Hans‐Georg Rammensee, Tobias A.W. Holderried, Lothar Kanz, Steve Pascolo, Peter Brossart	178
8	Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients 2006 ·Cancer Research ·Jan Wierecky, Martin Müller, Stefan Wirths, (unknown), Daniela Dörfel, Susanne M. Schmidt, Maik Häntschel, Wolfram Brugger, Stephen Schröder, Marius Horger, Lothar Kanz, Peter Brossart	185
9	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study 2004 ·Annals of Oncology ·Wolfram Brugger, Joy Hirsch, Frank Grünebach, Roland Repp, Peter Brossart, Wichard Vogel, Hans‐Georg Kopp, Markus G. Manz, Michael Bitzer, Günter Schlimok, Martin Kaufmann, Arnold Ganser, (unknown), Martin Gramatzki, Lothar Kanz	96
10	Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. 2003 ·PubMed ·Martin Müller, Frank Grünebach, Katrin Kayser, Wichard Vogel, Alessio Nencioni, Wolfram Brugger, Lothar Kanz, Peter Brossart	19
11	German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma 2002 ·Annals of Neurology ·Ulrich Herrlinger, Martin Schabet, Wolfram Brugger, Rolf‐Dieter Kortmann, Wilhelm Küker, Martina Deckert, Corinna Engel, (unknown), H.‐G. Mergenthaler, P. Krauseneck, (unknown), Christoph Meisner, Otmar D. Wiestler, J. Dichgans, Lothar Kanz, Michael Bamberg, Michael Weller	130
12	Ex Vivo Expansion of Normal Progenitor Cells from Acute Myeloid Leukemia Cell-Contaminated CD34 ⁺ Peripheral Blood Progenitor Cells after Mafosfamide Purging 2001 ·Journal of Hematotherapy & Stem Cell Research ·(unknown), Frank Grünebach, Peter Bader, Wichard Vogel, Lothar Kanz, Wolfram Brugger, Stefan Scheding	1
13	Primary central nervous system lymphoma 1991-1997 2001 ·Cancer ·Ulrich Herrlinger, Martin Schabet, Wolfram Brugger, Rolf‐Dieter Kortmann, Lothar Kanz, Michael Bamberg, J. Dichgans, Michael Weller	30
14	Ex vivo manipulation of hematopoietic stem and progenitor cells 2000 ·Seminars in Hematology ·Wolfram Brugger, Stefan Scheding, Benedikt Ziegler, Hans‐Jörg Bühring, Lothar Kanz	16
15	Functional response of leukaemic blasts to stromal cell‐derived factor‐1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia 2000 ·British Journal of Haematology ·Robert Möhle, Marcus M. Schittenhelm, (unknown), Frank Bautz, Karsten Kratz‐Albers, Hubert Serve, Wolfram Brugger, Lothar Kanz	129
16	Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34+ cells 2000 ·Experimental Hematology ·Stefan Scheding, Bernhard Meister, Hans‐Jörg Bühring, Charles M. Baum, (unknown), Thomas Böck, Lothar Kanz, Wolfram Brugger	18
17	How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? 1999 ·Experimental Hematology ·Stefan Scheding, (unknown), Diehl, Hans Wichmann, Wolfram Brugger, Lothar Kanz, Stephan Schmitz	23
18	Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report 1999 ·Annals of Oncology ·Sebastian Fetscher, Wolfram Brugger, R. Engelhardt, Lothar Kanz, J. Hasse, H Frommhold, W. Lange, Roland Mertelsmann	19
19	Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer 1997 ·Annals of Oncology ·Sebastian Fetscher, Wolfram Brugger, R. Engelhardt, Lothar Kanz, J. Hasse, H Frommhold, Michael Wenger, W. Lange, Roland Mertelsmann	35
20	Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow 1995 ·Blood ·Dorotheé von Laer, (unknown), Annerose Serr, Jürgen Finke, Lothar Kanz, AA Fauser, (unknown), Wolfram Brugger, F. Hufert	92

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact